Phase I safety and tolerability study of topical verapamil HCl in chronic rhinosinusitis with nasal polyps

Int Forum Allergy Rhinol. 2022 Aug;12(8):1071-1074. doi: 10.1002/alr.22959. Epub 2022 Jan 20.

Authors

Alan D Workman^{1

2}, Sarina K Mueller³, Kristen McDonnell^{1

2}, Jeremy W Goldfarb^{2

4}, Benjamin S Bleier^{1

2}

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
² Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Otolaryngology-Head and Neck Surgery, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), University Hospital Erlangen, Erlangen, Germany.
⁴ Department of Anesthesia, Massachusetts Eye and Ear, Boston, Massachusetts, USA.

PMID: 34990075
DOI: 10.1002/alr.22959

No abstract available

Keywords: CRSwNP; P-glycoprotein; P-gp; verapamil; verapamil HCl.

Publication types

Clinical Trial, Phase I
Research Support, N.I.H., Extramural

MeSH terms

Chronic Disease
Humans
Nasal Polyps* / drug therapy
Rhinitis* / drug therapy
Sinusitis* / drug therapy
Verapamil

Substances

Verapamil

Grants and funding

R01 NS108968/NS/NINDS NIH HHS/United States